BIO
Bio-Rad Laboratories Inc
NYSE: BIO · HEALTHCARE · MEDICAL DEVICES
$369.32
+0.15% today
Updated 2026-09-11
Market cap
$10.17B
P/E ratio
46.24
P/S ratio
3.93x
EPS (TTM)
$8.22
Dividend yield
—
52W range
$237 – $396
Volume
0.3M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C8.5
Quality
A5.0
Profitability
C+4.0
Valuation
C3/9
Piotroski F-Score
Weak
3.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$329.00
-10.92%
12-Month target
$271.22
-26.56%
Intrinsic (DCF)
$200.53
Margin of safety
-46.46%
1 Strong Buy0 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.36 — safe zone
+ Free cash flow $66.70M — positive
+ Debt/equity 0.17x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Revenue declining -0.10% QoQ
- 46.46% above intrinsic value
- P/E 46.24x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.80B | $2.67B | $2.57B | $2.58B | $2.59B |
| Net income | $-3.63B | $-637.32M | $-1.84B | $759.90M | $371.40M |
| EPS | — | — | — | — | $8.22 |
| Free cash flow | $80.29M | $218.26M | $266.20M | $374.60M | $66.70M |
| Profit margin | -129.45% | -23.86% | -71.86% | 29.42% | 8.59% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-01 | SCHWARTZ, NORMAN D | Sale | 3,005 | — |
| 2026-09-01 | SCHWARTZ, NORMAN D | Sale | 2,082 | — |
| 2026-09-01 | SCHWARTZ, NORMAN D | Buy | 5,087 | — |
Peer comparison
Smart narrative
Bio-Rad Laboratories Inc trades at $369.32. representing a P/E of 46.24x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.36, it sits in the safe zone. TTM revenue stands at $2.59B. with profit margins at 8.59%. Our DCF model estimates intrinsic value at $200.53.
Frequently asked questions
What is Bio-Rad Laboratories Inc's stock price?
Bio-Rad Laboratories Inc (BIO) trades at $369.32, on a P/E of 46.2x and a P/S of 3.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Bio-Rad Laboratories Inc overvalued?
Bio-Rad Laboratories Inc carries a Smart Value Score of 55/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $200.53 against the $369.32 price, so on cash flow terms the market is paying a premium for Bio-Rad Laboratories Inc's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Bio-Rad Laboratories Inc (BIO)?
The 12-month analyst consensus target is $329.00, about 10.9% below the current $369.32. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Bio-Rad Laboratories Inc (BIO)?
Our DCF model estimates intrinsic value at $200.53, a -46.5% margin of safety versus today's $369.32. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Bio-Rad Laboratories Inc's revenue?
Bio-Rad Laboratories Inc's trailing twelve-month revenue is $2.59B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Bio-Rad Laboratories Inc's Altman Z-Score is 3.36, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.93x
ROE2.46%
Beta1.07
50D MA$336.20
200D MA$302.00
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—